Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Licenses Asuragen's Sample-Preservation Product for Use with MammaPrint

NEW YORK (GenomeWeb News) - Asuragen said today it has granted global rights to Agendia for use of its RNARetain tissue preservation solution for human diagnostic applications.
Under the non-exclusive agreement, Agendia will use RNARetain to store and ship tumor samples for its MammaPrint diagnostic, which predicts the risk of the recurrence of breast cancer.
RNARetain, also known as RNAlater, is used to preserve nucleic acid profiles in solid tissues.
Agendia performs the MammaPrint analysis in its own lab using samples that physicians prepare and ship to its Amsterdam headquarters. According to the company’s website, MammaPrint analysis cannot be performed on formalin-fixed paraffin embedded tumor tissue “as this fixation procedure causes the RNA to degrade.”
Agendia received 510(k) clearance from the US Food and Drug Administration for MammaPrint earlier this year. It was the first assay the agency approved as an in vitro diagnostic multivariate assay since it released a draft guidance concerning the use of such devices last year.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.